Laurion Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-680,900
| Closed | -$126M | – | 233 |
|
|
2025
Q2 | $126M | Buy |
+680,900
| New | +$127M | 2.28% | 8 |
|
|
2024
Q3 | – | Sell |
-600,000
| Closed | -$103M | – | 279 |
|
|
2024
Q2 | $103M | Buy |
+600,000
| New | +$99.4M | 1.22% | 23 |
|
|
2024
Q1 | – | Sell |
-766,600
| Closed | -$119M | – | 511 |
|
|
2023
Q4 | $119M | Buy |
766,600
+166,600
| +28% | +$24.3M | 1.01% | 21 |
|
|
2023
Q3 | $89.4M | Hold |
600,000
| – | – | 0.55% | 44 |
|
|
2023
Q2 | $80.8M | Buy |
600,000
+450,000
| +300% | +$66M | 0.45% | 45 |
|
|
2023
Q1 | $23.9M | Buy |
+150,000
| New | +$22.9M | 0.16% | 124 |
|
|
2022
Q4 | – | Sell |
-1,329,900
| Closed | -$178M | – | 406 |
|
|
2022
Q3 | $178M | Buy |
1,329,900
+979,900
| +280% | +$141M | 1.05% | 30 |
|
|
2022
Q2 | $53.6M | Buy |
+350,000
| New | +$53.5M | 0.83% | 24 |
|
|
2022
Q1 | – | Sell |
-34,600
| Closed | -$4.68M | – | 518 |
|
|
2021
Q4 | $4.68M | Hold |
34,600
| – | – | 0.05% | 199 |
|
|
2021
Q3 | $3.73M | Buy |
+34,600
| New | +$3.95M | 0.02% | 375 |
|
|
2020
Q2 | – | Sell |
-718,000
| Closed | -$54.7M | – | 875 |
|
|
2020
Q1 | $54.7M | Sell |
718,000
-64,400
| -8% | -$5.49M | 0.6% | 32 |
|
|
2019
Q4 | $69.3M | Buy |
782,400
+441,600
| +130% | +$36.7M | 0.53% | 39 |
|
|
2019
Q3 | $25.8M | Buy |
340,800
+195,400
| +134% | +$13.4M | 0.19% | 120 |
|
|
2019
Q2 | $10.6M | Buy |
145,400
+123,700
| +570% | +$9.72M | 0.1% | 182 |
|
|
2019
Q1 | $1.75M | Buy |
21,700
+20,700
| +2,070% | +$1.69M | 0.02% | 396 |
|
|
2018
Q4 | $92K | Sell |
1,000
-212,600
| -100% | -$18.7M | ﹤0.01% | 1024 |
|
|
2018
Q3 | $20.2M | Sell |
213,600
-87,700
| -29% | -$8.32M | 0.2% | 108 |
|
|
2018
Q2 | $27.9M | Sell |
301,300
-1,200
| -0.4% | -$117K | 0.22% | 100 |
|
|
2018
Q1 | $28.6M | Sell |
302,500
-386,000
| -56% | -$42.4M | 0.23% | 107 |
|
|
2017
Q4 | $66.6M | Buy |
688,500
+394,400
| +134% | +$37.2M | 0.34% | 64 |
|
|
2017
Q3 | $26.1M | Sell |
294,100
-110,800
| -27% | -$8.43M | 0.12% | 151 |
|
|
2017
Q2 | $29.4M | Buy |
404,900
+124,900
| +45% | +$8.4M | 0.16% | 125 |
|
|
2017
Q1 | $18.2M | Buy |
280,000
+277,400
| +10,669% | +$17.4M | 0.14% | 183 |
|
|
2016
Q4 | $163K | Buy |
+2,600
| New | +$159K | ﹤0.01% | 1029 |
|
|
2016
Q1 | – | Sell |
-303,600
| Closed | -$18M | – | 754 |
|
|
2015
Q4 | $18M | Hold |
303,600
| – | – | 0.17% | 125 |
|
|
2015
Q3 | $16.5M | Sell |
303,600
-168,700
| -36% | -$11M | 0.19% | 107 |
|
|
2015
Q2 | $31.7M | Buy |
+472,300
| New | +$30.8M | 0.29% | 100 |
|
Other funds holding ABBV
VCM
VPM
Laurion Capital Management's ABBV Position: Q1 2026 in Review
Laurion Capital Management opened a new position in AbbVie (ABBV) in Q1 2026: 8,395 shares worth $1.83M. The stake represents 0.08% of the portfolio and ranks #221 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in ABBV as recently as Q2 2024.
Laurion Capital Management first reported a position in ABBV in Q2 2015 and has held it in 21 quarters since. The position peaked at $49.5M in Q2 2016. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Laurion Capital Management held 8,395 shares of AbbVie worth $1.83M as of Q1 2026.
- AbbVie was a new Laurion Capital Management position in Q1 2026.
- AbbVie made up 0.08% of Laurion Capital Management's portfolio in Q1 2026, its #221 holding.
- Laurion Capital Management first reported a position in AbbVie in Q2 2015 and has held it in 21 quarters since.
- Laurion Capital Management's AbbVie position peaked at $49.5M in Q2 2016.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.